{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:22:03Z","timestamp":1774084923954,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.<\/jats:p>","DOI":"10.1038\/s41598-020-66440-9","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T06:02:46Z","timestamp":1591682566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic"],"prefix":"10.1038","volume":"10","author":[{"given":"Rodrigo","family":"J\u00e1come","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Alberto","family":"Campillo-Balderas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Ponce de Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Becerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Lazcano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"key":"66440_CR1","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.idc.2019.07.001","volume":"33","author":"DSC Hui","year":"2019","unstructured":"Hui, D. S. C. & Zumla, A. Severe acute respiratory syndrome: historical, epidemiological and clinical features. Infect. Dis. Clin. N. Am. 33, 869\u2013889 (2019).","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"66440_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.idc.2019.08.001","volume":"33","author":"EI Ashar","year":"2019","unstructured":"Ashar, E. I., Hui, D. S. C., Memish, Z. A. & Zumla, A. The Middle East respiratory syndrome (MERS). Infect. Dis. Clin. N. Am. 33, 891\u2013905 (2019).","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"66440_CR3","unstructured":"WHO. Coronavirus disease (COVID-19) Situation dashboard \u2013 April 18th, 2020, https:\/\/covid19.who.int\/ (2020)."},{"key":"66440_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijid.2019.07.033","volume":"87","author":"R J\u00e1come","year":"2019","unstructured":"J\u00e1come, R. et al. A yellow flag on the horizon: the looming threat of yellow fever to North America. Int. J. Infect. Dis. 87, 143\u2013150 (2019).","journal-title":"Int. J. Infect. Dis."},{"key":"66440_CR5","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3389\/fmicb.2019.01813","volume":"10","author":"NS Ogando","year":"2019","unstructured":"Ogando, N. S. et al. The curious case of the Nidovirus exoribonuclease: its role in RNA synthesis and replication fidelity. Front. Microbiol. 10, 1813 (2019).","journal-title":"Front. Microbiol."},{"key":"66440_CR6","unstructured":"WHO. Solidarity clinical trial for the COVID-19 treatments, https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov\/solidarity-clinical-trial-for-covid-19-treatments (2020)"},{"key":"66440_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10280-3","volume":"10","author":"RN Kirchdoerfer","year":"2019","unstructured":"Kirchdoerfer, R. N. & Ward, A. B. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 cofactors. Nat. Commun. 10, 2342 (2019).","journal-title":"Nat. Commun."},{"key":"66440_CR8","doi-asserted-by":"publisher","first-page":"e0139001","DOI":"10.1371\/journal.pone.0139001","volume":"10","author":"R J\u00e1come","year":"2015","unstructured":"J\u00e1come, R., Becerra, A., Ponce de Le\u00f3n, S. & Lazcano, A. Structural analysis of monomeric RNA-dependent polymerases: evolutionary and therapeutic implications. PLoS ONE 10, e0139001 (2015).","journal-title":"PLoS ONE"},{"key":"66440_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Y Furuta","year":"2017","unstructured":"Furuta, Y., Komeno, T. & Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B. 93, 449\u2013463 (2017).","journal-title":"Proc. Jpn. Acad. Ser. B."},{"key":"66440_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in Rhesus monkeys. Nature. 531, 381\u2013385 (2016).","journal-title":"Nature."},{"key":"66440_CR11","doi-asserted-by":"publisher","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","volume":"9","author":"ML Agostini","year":"2018","unstructured":"Agostini, M. L. et al. Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exonuclease. mBio. 9, e00221\u201318 (2018).","journal-title":"mBio."},{"key":"66440_CR12","doi-asserted-by":"publisher","unstructured":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., https:\/\/doi.org\/10.1038\/s41422-020-0282-0 (2020)","DOI":"10.1038\/s41422-020-0282-0"},{"key":"66440_CR13","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1126\/science.1259210","volume":"347","author":"TC Appleby","year":"2015","unstructured":"Appleby, T. C. et al. Structural basis for RNA replication by the Hepatitis C virus polymerase. Science. 347, 771\u2013775 (2015).","journal-title":"Science."},{"key":"66440_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/cbdd.13091","volume":"91","author":"CS Gan","year":"2018","unstructured":"Gan, C. S., Lim, S. K., Chee, C. F., Yusof, R. & Heh, C. H. Sofosbuvir as treatment against Dengue? Chem. Bio. Drug Des. 91, 448\u2013455 (2018).","journal-title":"Chem. Bio. Drug Des."},{"key":"66440_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19526-4","volume":"8","author":"P Mesci","year":"2018","unstructured":"Mesci, P. et al. Blocking Zika virus vertical transmission. Sci. Rep. 8, 1218 (2018).","journal-title":"Sci. Rep."},{"key":"66440_CR16","doi-asserted-by":"publisher","first-page":"104708","DOI":"10.1016\/j.antiviral.2020.104708","volume":"175","author":"F Dragoni","year":"2020","unstructured":"Dragoni, F. et al. Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. Antiviral Res. 175, 104708 (2020).","journal-title":"Antiviral Res."},{"key":"66440_CR17","doi-asserted-by":"publisher","first-page":"117477","DOI":"10.1016\/j.lfs.2020.117477","volume":"148","author":"AA Elfiky","year":"2020","unstructured":"Elfiky, A. A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 148, 117477 (2020).","journal-title":"Life Sci."},{"key":"66440_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-00444-3","author":"A Maxmen","year":"2020","unstructured":"Maxmen, A. More than 80 clinical trials launch to test coronavirus treatment. Nature https:\/\/doi.org\/10.1038\/d41586-020-00444-3 (2020).","journal-title":"Nature"},{"key":"66440_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14218\/JCTH.2014.00041","volume":"3","author":"T McQuaid","year":"2015","unstructured":"McQuaid, T., Savini, C. & Seyedkazemi, S. Sofosbuvir, a significant paradigm change in HCV treatment. J. Clin. Transl. Hepatol. 3, 27\u201335 (2015).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"66440_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/hep.27375","volume":"61","author":"EF Donaldson","year":"2015","unstructured":"Donaldson, E. F., Harrington, P. R., O\u2019Rear, J. J. & Naeger, L. K. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 61, 56\u201365 (2015).","journal-title":"Hepatology"},{"key":"66440_CR21","doi-asserted-by":"publisher","first-page":"e1003565","DOI":"10.1371\/journal.ppat.1003565","volume":"9","author":"E Clinton Smith","year":"2013","unstructured":"Clinton Smith, E., Blanc, H., Surdel, M. C., Vignuzzi, M. & Denison, M. R. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog. 9, e1003565 (2013).","journal-title":"PLoS Pathog."},{"key":"66440_CR22","doi-asserted-by":"publisher","unstructured":"Shu, Y., McCauley, J. GISAID: Global initiative on sharing all influenza data \u2013 from vision to reality. EuroSurveillance, 22, https:\/\/doi.org\/10.2807\/1560-7917.ES.2017.22.13.30494 (2017).","DOI":"10.2807\/1560-7917.ES.2017.22.13.30494"},{"key":"66440_CR23","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/molbev\/msy096","volume":"35","author":"S Kumar","year":"2018","unstructured":"Kumar, S., Stecher, G., Li, M., Knyaz, C. & Tamura, K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol. Biol. Evol. 35, 1547\u20131549 (2018).","journal-title":"Mol. Biol. Evol."},{"key":"66440_CR24","first-page":"95","volume":"41","author":"TA Hall","year":"1999","unstructured":"Hall, T. A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT. Nucl. Acids Symp. Ser. 41, 95\u201398 (1999).","journal-title":"Nucl. Acids Symp. Ser."},{"key":"66440_CR25","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera \u2013 a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"66440_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-7-339","volume":"7","author":"EC Meng","year":"2006","unstructured":"Meng, E. C., Pettersen, E. F., Couch, G. S., Huang, C. C. & Ferrin, T. E. Tools for integrated sequence-structure analysis with UCSF Chimera. BMC Bioinformatics. 7, 339 (2006).","journal-title":"BMC Bioinformatics."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66440-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66440-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66440-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:00:32Z","timestamp":1670310032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66440-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["66440"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-66440-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-21002\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"3 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9294"}}